Logo image of ZEPP

ZEPP HEALTH CORP-ADR (ZEPP) Stock Fundamental Analysis

NYSE:ZEPP - New York Stock Exchange, Inc. - US98945L2043 - ADR - Currency: USD

14  +4.43 (+46.29%)

After market: 14.13 +0.13 (+0.93%)

Fundamental Rating

1

Overall ZEPP gets a fundamental rating of 1 out of 10. We evaluated ZEPP against 125 industry peers in the Electronic Equipment, Instruments & Components industry. ZEPP has a bad profitability rating. Also its financial health evaluation is rather negative. ZEPP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ZEPP has reported negative net income.
In multiple years ZEPP reported negative net income over the last 5 years.
In multiple years ZEPP reported negative operating cash flow during the last 5 years.
ZEPP Yearly Net Income VS EBIT VS OCF VS FCFZEPP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

ZEPP's Return On Assets of -15.60% is on the low side compared to the rest of the industry. ZEPP is outperformed by 68.00% of its industry peers.
ZEPP has a Return On Equity of -34.90%. This is in the lower half of the industry: ZEPP underperforms 72.80% of its industry peers.
Industry RankSector Rank
ROA -15.6%
ROE -34.9%
ROIC N/A
ROA(3y)-8.27%
ROA(5y)-3.78%
ROE(3y)-16.67%
ROE(5y)-7.49%
ROIC(3y)N/A
ROIC(5y)N/A
ZEPP Yearly ROA, ROE, ROICZEPP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 -30

1.3 Margins

ZEPP's Gross Margin of 38.83% is fine compared to the rest of the industry. ZEPP outperforms 68.00% of its industry peers.
In the last couple of years the Gross Margin of ZEPP has grown nicely.
The Profit Margin and Operating Margin are not available for ZEPP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.57%
GM growth 5Y8.78%
ZEPP Yearly Profit, Operating, Gross MarginsZEPP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

More info and screens

2

2. Health

2.1 Basic Checks

ZEPP does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZEPP has less shares outstanding than it did 1 year ago.
ZEPP has less shares outstanding than it did 5 years ago.
ZEPP has a worse debt/assets ratio than last year.
ZEPP Yearly Shares OutstandingZEPP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ZEPP Yearly Total Debt VS Total AssetsZEPP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.33, we must say that ZEPP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.33, ZEPP is not doing good in the industry: 74.40% of the companies in the same industry are doing better.
ZEPP has a Debt/Equity ratio of 0.79. This is a neutral value indicating ZEPP is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.79, ZEPP is not doing good in the industry: 88.80% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z 1.33
ROIC/WACCN/A
WACC7.03%
ZEPP Yearly LT Debt VS Equity VS FCFZEPP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ZEPP has a Current Ratio of 1.14. This is a normal value and indicates that ZEPP is financially healthy and should not expect problems in meeting its short term obligations.
ZEPP has a worse Current ratio (1.14) than 90.40% of its industry peers.
ZEPP has a Quick Ratio of 1.14. This is a bad value and indicates that ZEPP is not financially healthy enough and could expect problems in meeting its short term obligations.
ZEPP has a Quick ratio of 0.84. This is amonst the worse of the industry: ZEPP underperforms 86.40% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 0.84
ZEPP Yearly Current Assets VS Current LiabilitesZEPP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

0

3. Growth

3.1 Past

ZEPP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.78%.
Looking at the last year, ZEPP shows a very negative growth in Revenue. The Revenue has decreased by -39.15% in the last year.
The Revenue for ZEPP have been decreasing by -26.33% on average. This is quite bad
EPS 1Y (TTM)-34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.8%
Revenue 1Y (TTM)-39.15%
Revenue growth 3Y-42.67%
Revenue growth 5Y-26.33%
Sales Q2Q%-86.61%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y62.54%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.24%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZEPP Yearly Revenue VS EstimatesZEPP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B
ZEPP Yearly EPS VS EstimatesZEPP Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZEPP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZEPP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZEPP Price Earnings VS Forward Price EarningsZEPP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZEPP Per share dataZEPP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ZEPP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZEPP HEALTH CORP-ADR

NYSE:ZEPP (7/15/2025, 4:32:02 PM)

After market: 14.13 +0.13 (+0.93%)

14

+4.43 (+46.29%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)05-19 2025-05-19/bmo
Earnings (Next)08-20 2025-08-20
Inst Owners28.98%
Inst Owner Change0%
Ins Owners5.91%
Ins Owner ChangeN/A
Market Cap839.72M
Analysts82.86
Price Target12.57 (-10.21%)
Short Float %0.12%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.18%
PT rev (3m)-15.9%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.62
P/FCF N/A
P/OCF N/A
P/B 3.62
P/tB 4.05
EV/EBITDA N/A
EPS(TTM)-1.34
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.03
BVpS3.87
TBVpS3.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.6%
ROE -34.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.83%
FCFM N/A
ROA(3y)-8.27%
ROA(5y)-3.78%
ROE(3y)-16.67%
ROE(5y)-7.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.57%
GM growth 5Y8.78%
F-ScoreN/A
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 0.84
Altman-Z 1.33
F-ScoreN/A
WACC7.03%
ROIC/WACCN/A
Cap/Depr(3y)22.81%
Cap/Depr(5y)96.65%
Cap/Sales(3y)0.51%
Cap/Sales(5y)0.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.8%
EPS Next Y62.54%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-39.15%
Revenue growth 3Y-42.67%
Revenue growth 5Y-26.33%
Sales Q2Q%-86.61%
Revenue Next Year19.24%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-103.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-162.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-156.9%
OCF growth 3YN/A
OCF growth 5YN/A